PHIO PHARMACEUTICALS CORP.

Profile

Company Names

PHIO PHARMACEUTICALS CORP.
RXI PHARMACEUTICALS CORP

Addresses

411 SWEDELAND ROAD, SUITE 23-1080, KING OF PRUSSIA, PA 19406

11 APEX DRIVE, SUITE 300A, PMB 2006, MARLBOROUGH, MA 01752

11 APEX DRIVE, SUITE 300A, PMB 2006, MARLBOROUGH, MA 01752

257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH, MA 01752

257 SIMARANO DRIVE, SUITE 101, MARLBOROUGH, MA 01752

1500 WEST PARK DRIVE, SUITE 210, WESTBOROUGH, MA 01581

Phone Numbers

(508) 767-3861
508-767-3861

 

Entity Type:

CORPORATION

Industry:

BIOTECHNOLOGY, PHARMACEUTICALS

Year Incorporated:

2011

State Incorporated:

DELAWARE

Total Amount Raised:

$55,259,823.00

Number of Funding Rounds:

14
Investment Rounds
Round #
Round Open Date
Amount Raised
Total Round Size
Amount Remaining to be Raised
Securities
14
2025-11-04 
$1,415,796.00 
$25,931,342.00 
$24,515,546.00 
 
13
2025-07-28 
$232,149.00 
$5,080,826.00 
$4,848,677.00 
 
12
2024-12-24 
$30,000.00 
$480,000.00 
$450,000.00 
 
11
2024-12-20 
$54,649.00 
$1,314,650.00 
$1,260,001.00 
 
10
2024-07-11 
$136,322.00 
$6,358,543.00 
$6,222,221.00 
 
9
2023-12-08 
$532,563.00 
$5,399,124.00 
$4,866,561.00 
 
8
2023-06-02 
$2,999,373.00 
$10,907,728.00 
$7,908,355.00 
Equity 
7
2023-04-20 
$4,010,519.00 
$4,010,519.00 
$0.00 
 
6
2022-11-16 
$1,750.00 
$1,750.00 
$0.00 
Equity 
5
2021-01-25 
$14,001,909.00 
$24,264,137.00 
$10,262,228.00 
Equity 
4
2020-04-02 
$4,375,011.00 
$4,375,011.00 
$0.00 
 
3
2020-02-06 
$1,903,128.00 
$1,903,128.00 
$0.00 
 
2
2017-08-08 
$1,937,904.00 
$15,261,000.00 
$13,323,096.00 
Equity 
1
2013-03-12 
$23,628,750.00 
$23,628,750.00 
$0.00 
Equity 
People
First Name
Middle Name
Last Name
Titles
Related Companies
ROBERT 
 
BITTERMAN 
DIRECTOR
RXI PHARMACEUTICALS CORP
ROBERT 
J 
BITTERMAN 
DIRECTOR, EXECUTIVE OFFICER
PHIO PHARMACEUTICALS CORP.
ROBERT 
J. 
BITTERMAN 
DIRECTOR, EXECUTIVE OFFICER
CUTANEA LIFE SCIENCES INC   |  PHIO PHARMACEUTICALS CORP.
PATRICIA 
A 
BRADFORD 
DIRECTOR
PHIO PHARMACEUTICALS CORP.
PATRICIA 
A. 
BRADFORD 
DIRECTOR
PHIO PHARMACEUTICALS CORP.
KEITH 
 
BROWNLIE 
DIRECTOR
RXI PHARMACEUTICALS CORP
LISA 
 
CARSON 
EXECUTIVE OFFICER
PHIO PHARMACEUTICALS CORP.
GEERT 
 
CAUWENBERGH 
DIRECTOR, EXECUTIVE OFFICER
CUTANEA LIFE SCIENCES INC   |  RXI PHARMACEUTICALS CORP   |  PHIO PHARMACEUTICALS CORP.
DAVID 
H. 
DEMING 
DIRECTOR
IRX THERAPEUTICS, INC.   |  PHIO PHARMACEUTICALS CORP.
GERRIT 
 
DISPERSYN 
EXECUTIVE OFFICER, DIRECTOR
RXI PHARMACEUTICALS CORP   |  PHIO PHARMACEUTICALS CORP.
H 
PAUL 
DORMAN 
DIRECTOR
PHIO PHARMACEUTICALS CORP.
H. 
PAUL 
DORMAN 
DIRECTOR
PHIO PHARMACEUTICALS CORP.
PAUL 
 
DORMAN 
DIRECTOR
RXI PHARMACEUTICALS CORP
ALEXEY 
 
ELISEEV 
EXECUTIVE OFFICER
RXI PHARMACEUTICALS CORP
ROBERT 
 
FERRARA 
DIRECTOR
PHIO PHARMACEUTICALS CORP.
ROBERT 
L 
FERRARA 
DIRECTOR
PHIO PHARMACEUTICALS CORP.
ROBERT 
L. 
FERRARA 
DIRECTOR
PHIO PHARMACEUTICALS CORP.
JONATHAN 
 
FREEMAN 
DIRECTOR
RXI PHARMACEUTICALS CORP   |  PHIO PHARMACEUTICALS CORP.
JONATHAN 
E 
FREEMAN 
DIRECTOR
PHIO PHARMACEUTICALS CORP.
JONATHAN 
E. 
FREEMAN 
DIRECTOR
PHIO PHARMACEUTICALS CORP.
ROBERT 
 
INFARINATO 
EXECUTIVE OFFICER
PHIO PHARMACEUTICALS CORP.
CAITLIN 
 
KONTULIS 
EXECUTIVE OFFICER
RXI PHARMACEUTICALS CORP   |  PHIO PHARMACEUTICALS CORP.
CURTIS 
 
LOCKSHIN 
DIRECTOR
QUIKBYTE SOFTWARE INC   |  CHROMADEX CORP.   |  RXI PHARMACEUTICALS CORP   |  XENETIC BIOSCIENCES, INC.
CURTIS 
A 
LOCKSHIN 
DIRECTOR
PHIO PHARMACEUTICALS CORP.
CURTIS 
A. 
LOCKSHIN 
DIRECTOR
CHROMADEX CORP.   |  PHIO PHARMACEUTICALS CORP.
CURTIS 
 
LOCKSHIN, PH.D. 
DIRECTOR
SORRENTO THERAPEUTICS, INC.   |  PHIO PHARMACEUTICALS CORP.
CURTIS 
A. 
LOCKSHIN, PH.D. 
DIRECTOR
PHIO PHARMACEUTICALS CORP.
PAMELA 
 
PAVCO 
EXECUTIVE OFFICER
RXI PHARMACEUTICALS CORP
Filings
Filing Date
Filing Type
Source URL
Industry Classifier
Detailed Industry
Revenue Range
Securities
First Sale Date
2025-11-12
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2025-11-04 
2025-08-04
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2025-07-28 
2025-01-07
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2024-12-24 
2025-01-03
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2024-12-20 
2024-07-24
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2024-07-11 
2023-12-19
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
NO REVENUES 
 
2023-12-08 
2023-06-13
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
NO REVENUES 
Equity 
2023-06-02 
2023-05-02
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
NO REVENUES 
 
2023-04-20 
2022-11-23
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
NO REVENUES 
Equity 
2022-11-16 
2021-02-16
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2021-01-25 
2020-04-14
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2020-04-02 
2020-02-24
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
 
2020-02-06 
2018-08-17
D/A
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2017-08-08 
2017-08-18
D
Link
PHARMACEUTICALS 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2017-08-08 
2013-03-26
D
Link
BIOTECHNOLOGY 
PHARMACEUTICAL PREPARATIONS [2834] 
DECLINE TO DISCLOSE 
Equity 
2013-03-12 
Brokers
Broker Dealer
Broker CRD#
Recipient Name
Recipient CRD#
NONE
NONE
H.C. WAINWRIGHT + CO, LLC
375
NONE
NONE
H.C. WAINWRIGHT + CO., LLC
375
NONE
NONE
H.C. WAINWRIGHT + CO., LLC
375
NONE
NONE
H.C. WAINWRIGHT + CO., LLC
375
NONE
NONE
MTS SECURITIES, LLC
104059